Shares of Evotec SE (EVO) plummeted 14.86% in Wednesday's trading session, as investors reacted strongly to the company's underwhelming third-quarter financial results and news of a strategic asset sale. The German biotech firm's stock price decline significantly outpaced the 9.57% drop observed in pre-market trading, indicating a continued sell-off throughout the day.

Evotec's Q3 earnings report revealed concerning figures that fell short of market expectations. The company reported quarterly losses of $0.14 per share, meeting analyst expectations but representing a 16.67% increase in losses compared to the same period last year. More alarmingly, Evotec's quarterly revenue came in at $191.62 million, missing the analyst consensus estimate of $237.32 million by a substantial 19.26%. This also marked a 5.71% decrease from the $203.21 million in sales reported in the same quarter of the previous year, signaling potential challenges in the company's core business operations.

Adding to investor concerns, Evotec announced the sale of its Just – Evotec Biologics Toulouse site to Sandoz (SDZNY). While the company framed this as a successful transaction, it appears to have raised questions about Evotec's strategic direction and future growth prospects. The combination of weak quarterly results, missed sales targets, and the divestment of assets seems to have significantly shaken investor confidence, leading to the sharp decline in Evotec's stock price. As the market digests this news, investors will be closely watching for any further updates or guidance from the company regarding its plans to address these challenges and return to growth.